Denglong Wu Selected Research

Androgens

1/2024	Glycolysis related lncRNA SNHG3 / miR-139-5p / PKM2 axis promotes castration-resistant prostate cancer (CRPC) development and enzalutamide resistance.
7/2022	CDK6 is upregulated and may be a potential therapeutic target in enzalutamide-resistant castration-resistant prostate cancer.
3/2022	High-dose-androgen-induced autophagic cell death to suppress the Enzalutamide-resistant prostate cancer growth via altering the circRNA-BCL2/miRNA-198/AMBRA1 signaling.
1/2022	Inhibiting 3βHSD1 to eliminate the oncogenic effects of progesterone in prostate cancer.
11/2021	Suppressing BCL-XL increased the high dose androgens therapeutic effect to better induce the Enzalutamide-resistant prostate cancer autophagic cell death.
1/2021	Histone acetyltransferase 1 upregulates androgen receptor expression to modulate CRPC cell resistance to enzalutamide.
1/2021	Tracing steroidogenesis in prostate biopsy samples to unveil prostate tissue androgen metabolism characteristics and potential clinical application.
1/2020	A Novel Androgen-Induced lncRNA FAM83H-AS1 Promotes Prostate Cancer Progression via the miR-15a/CCNE2 Axis.
1/2019	CircRNA-UCK2 Increased TET1 Inhibits Proliferation and Invasion of Prostate Cancer Cells Via Sponge MiRNA-767-5p.
1/2019	Functional Silencing of HSD17B2 in Prostate Cancer Promotes Disease Progression.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Denglong Wu Research Topics

Disease

32	Prostatic Neoplasms (Prostate Cancer) 02/2024 - 12/2012
13	Neoplasms (Cancer) 01/2024 - 11/2013
4	Carcinoma (Carcinomatosis) 01/2021 - 12/2012
3	Urinary Bladder Neoplasms (Bladder Cancer) 01/2017 - 04/2005
2	Prostatic Hyperplasia (Benign Prostatic Hyperplasia) 02/2024 - 05/2016
2	Urethral Stricture 01/2021 - 01/2016
2	Carcinogenesis 08/2020 - 01/2020
2	Neoplasm Metastasis (Metastasis) 01/2019 - 02/2016
1	Disease Progression 01/2022
1	Fibrosis (Cirrhosis) 01/2021
1	Cicatrix (Scar) 01/2021
1	Renal Cell Carcinoma (Grawitz Tumor) 08/2020
1	Adenocarcinoma 01/2020
1	Obesity 01/2018
1	Hypogonadism (Hypergonadotropic Hypogonadism) 01/2018
1	Weight Loss (Weight Reduction) 01/2018
1	Hyperglycemia 08/2016
1	Wounds and Injuries (Trauma) 08/2016
1	Body Weight (Weight, Body) 08/2016
1	Hemorrhage 05/2016
1	Leukemia 02/2016
1	Pathologic Processes 01/2015
1	Seminoma 01/2014
1	Aneuploidy (Aneuploid) 01/2014
1	Chromosome Aberrations (Chromosome Abnormalities) 01/2014
1	Inborn Genetic Diseases (Disease, Hereditary) 01/2014
1	Genomic Instability 05/2013

Drug/Important Bio-Agent (IBA)

12	AndrogensIBA 01/2024 - 01/2016
10	enzalutamideIBA 01/2024 - 01/2019
7	MicroRNAs (MicroRNA)IBA 01/2024 - 01/2015
5	Proteins (Proteins, Gene)FDA Link 10/2023 - 04/2005
5	Androgen Receptors (Androgen Receptor)IBA 10/2022 - 01/2016
4	Long Noncoding RNAIBA 01/2024 - 01/2014
3	Hormones (Hormone)IBA 02/2024 - 01/2022
3	EnzymesIBA 01/2024 - 05/2015
3	abirateroneIBA 08/2022 - 01/2022
3	Circular RNAIBA 03/2022 - 01/2019
3	RNA (Ribonucleic Acid)IBA 01/2022 - 01/2014
2	ProlactinIBA 02/2024 - 01/2022
2	Glucose (Dextrose)FDA LinkGeneric 01/2024 - 01/2018
2	Dehydroepiandrosterone (DHEA)IBA 12/2023 - 05/2015
2	UbiquitinIBA 10/2022 - 11/2013
2	Therapeutic UsesIBA 11/2021 - 08/2016
2	Androgen Antagonists (Antiandrogens)IBA 11/2021 - 01/2019
2	LipidsIBA 09/2021 - 03/2017
2	Biomarkers (Surrogate Marker)IBA 01/2021 - 01/2017
2	Small Interfering RNA (siRNA)IBA 08/2016 - 01/2015
1	IsoenzymesIBA 01/2024
1	Pyruvate KinaseIBA 01/2024
1	EquilinIBA 12/2023
1	NucleophosminIBA 10/2023
1	CopperIBA 01/2023
1	Ligases (Synthetase)IBA 10/2022
1	Protein Isoforms (Isoforms)IBA 10/2022
1	celastrolIBA 10/2022
1	Steroid Receptors (Steroid Receptor)IBA 10/2022
1	Glucocorticoid Receptors (Glucocorticoid Receptor)IBA 10/2022
1	Prostate-Specific Antigen (Semenogelase)IBA 08/2022
1	Prednisone (Sone)FDA LinkGeneric 08/2022
1	Dutasteride (Avodart)FDA Link 08/2022
1	Histone MethyltransferasesIBA 07/2022
1	Progesterone FDA LinkGeneric 01/2022
1	CollagenIBA 09/2021
1	Hemoglobins (Hemoglobin)IBA 09/2021
1	Triamcinolone Acetonide (Azmacort)FDA LinkGeneric 01/2021
1	Fluorouracil (Carac)FDA LinkGeneric 01/2021
1	Histone Acetyltransferases (Histone Acetyltransferase)IBA 01/2021
1	Phosphotransferases (Kinase)IBA 08/2020
1	Oncogene Proteins (Oncogene Protein)IBA 01/2020
1	Insulin (Novolin)FDA Link 01/2018
1	GTP Phosphohydrolases (GTPases)IBA 01/2017
1	Complement Factor B (Factor B)IBA 01/2017
1	ran-binding protein 1IBA 01/2017
1	Blood Glucose (Blood Sugar)IBA 08/2016
1	Urea (Carbamide)FDA LinkGeneric 08/2016
1	GlycogenIBA 08/2016
1	NitrogenIBA 08/2016
1	Proto-Oncogene Proteins c-pim-1 (Proto Oncogene Proteins c pim 1)IBA 02/2016
1	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA 02/2016
1	CateninsIBA 01/2016
1	SteroidsIBA 05/2015
1	Dihydrotestosterone (Androstanolone)IBA 05/2015
1	Oxidoreductases (Dehydrogenase)IBA 05/2015
1	Prostaglandins DIBA 01/2014
1	Stem Cell FactorIBA 01/2014
1	Epidermal Growth Factor (EGF)IBA 01/2014
1	Leukemia Inhibitory FactorIBA 01/2014
1	Cholera ToxinIBA 01/2014
1	Peptide Hydrolases (Proteases)FDA Link 11/2013
1	ChromatinIBA 05/2013
1	HMGB1 Protein (HMG1)IBA 12/2012

Therapy/Procedure

10	Castration 01/2024 - 05/2015
10	Therapeutics 01/2024 - 01/2016
4	Prostatectomy (Retropubic Prostatectomy) 02/2016 - 09/2002
1	Gastrectomy 01/2018
1	Length of Stay 05/2016
1	Semiconductor Lasers 05/2016
1	Immunotherapy 02/2016
1	Minimally Invasive Surgical Procedures 01/2016
1	Radiotherapy 01/2014